China Universal Asset Management Co., Ltd. Allakos Inc. Transaction History

China Universal Asset Management Co., Ltd.

$893 Million
Q3 2024

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 May 21, 2024	BUY	$2.13 - $5.55 $2,323 - $6,055	1,091 Added 96.21%	2,225 $5,000
Q3 2023 Oct 30, 2023	BUY	$2.13 - $5.55 $2,323 - $6,055	1,091 Added 96.21%	2,225 $5,000
Q2 2023 May 21, 2024	SELL	$3.6 - $5.25 $72 - $105	-20 Reduced 1.73%	1,134 $4,000
Q2 2023 Jul 27, 2023	SELL	$3.6 - $5.25 $72 - $105	-20 Reduced 1.73%	1,134 $5,000
Q1 2023 May 21, 2024	BUY	$4.3 - $8.27 $1,242 - $2,390	289 Added 33.41%	1,154 $5,000
Q1 2023 Apr 27, 2023	BUY	$4.3 - $8.27 $1,242 - $2,390	289 Added 33.41%	1,154 $5,000
Q4 2022 May 21, 2024	BUY	$5.66 - $8.42 $4,895 - $7,283	865 New	865 $7,000
Q4 2022 Jan 31, 2023	BUY	$5.66 - $8.42 $1,986 - $2,955	351 Added 68.29%	865 $7,000
Q3 2022 Oct 21, 2022	BUY	$3.02 - $6.12 $1,552 - $3,145	514 New	514 $3,000

Others Institutions Holding ALLK

# of Institutions

Shares Held

64.7M

Call Options Held

47.1K

Put Options Held

Bvf Inc San Francisco, CA

16.6M
Shares

$17.5 Million
0.34% of portfolio
Nea Management Company, LLC Timonium, MD

6.15M
Shares

$6.52 Million
0.31% of portfolio
Deep Track Capital, LP Greenwich, CT

5M
Shares

$5.3 Million
0.12% of portfolio
Vanguard Group Inc Valley Forge, PA

3.51M
Shares

$3.73 Million
0.0% of portfolio
Redmile Group, LLC San Francisco, CA

3.08M
Shares

$3.26 Million
0.13% of portfolio

View Full List

About Allakos Inc.

Ticker ALLK
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 84,726,096
Market Cap $89.8M
Description
Allakos Inc., a clinical stage biopharmaceutical company, develops therapeutics that target immunomodulatory receptors present on immune effector cells in allergy, inflammatory, and proliferative diseases. The company's lead monoclonal antibody is lirentelimab (AK002), which is in a Phase III study for the treatment of eosinophilic gastritis and...

More about ALLK

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of China Universal Asset Management Co., Ltd., based on Form 13F filings with the SEC.

News

Stay updated on China Universal Asset Management Co., Ltd. with notifications on news.

Account